Communiqués Evelo Biosciences, Inc.

Actions

EVLO

US2997342025

Recherche biotechnologique et médicale

Temps Différé OTC Markets 19:17:00 22/09/2026			Varia. 5j.	Varia. 1 janv.
0,000100 ^USD	-66,67 %		0,00 %	-80,00 %

21/11/23	Evelo Biosciences, Inc. annonce la cessation des fonctions de Simba Gill en tant que Chief Executive Officer	CI
21/11/23	Evelo Biosciences, Inc. annonce des changements au sein de sa direction, avec effet au 1er décembre 2023	CI

Communiqués

17/10/23	Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	AQ
14/08/23	Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights	AQ
12/07/23	Evelo Biosciences Closes $25.5 Million Private Placement	AQ
10/07/23	Evelo Biosciences Announces $25.5 Million Private Placement	AQ
29/06/23	Evelo Biosciences Announces Reverse Stock Split Effective	AQ
29/06/23	Evelo Biosciences Announces Reverse Stock Split Effective	GL
23/06/23	Evelo Biosciences : Other Information - Form 8-K	PU
16/06/23	Evelo Biosciences : Other Information - Form 8-K	PU
08/06/23	EVELO BIOSCIENCES, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
31/05/23	Evelo Biosciences : Other Information - Form 8-K	PU
23/05/23	Evelo Biosciences : Other Information - Form 8-K	PU
01/05/23	EVELO BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
26/04/23	Evelo Biosciences Provides Clinical Updates	GL
18/04/23	EVELO BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
17/03/23	Evelo Biosciences : Failure to Satisfy Listing Rule - Form 8-K	PU
17/03/23	EVELO BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
16/03/23	EVELO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
16/03/23	Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights	AQ
16/03/23	Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights	GL
09/03/23	Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023	GL
01/03/23	Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference	GL
01/03/23	Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference	GL
27/02/23	Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial	GL
27/02/23	Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial	GL
17/02/23	EVELO BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	AQ